am -
pm ET

Let’s Work Together

Alnylam Assist™ knows how important one on-one interactions are, which is why we have Case Managers and Patient Education Liaisons (PELs) to provide product education, tools to connect with the community, and resources that can help you during treatment.

Alnylam Assist® Case Managers

Alnylam Case Managers

Once you and your doctor choose to start treatment with OXLUMO® (lumasiran) you will be partnered with a Case Manager. Case Managers are trained professionals whose expertise is in helping patients get started on treatment and providing product support. They will tailor their method of communication to what works best for you

A Case Manager will help you understand your insurance coverage benefits and verify them for you. They can also inform you about options for financial support that you may be eligible for as well as provide you with educational resources. In addition, Case Managers can connect you with a PEL. 

Alnylam Assist® Case Manager Kevin

Meet Your Local Case ManagerRead Kevin's Bio ›

Alnylam Assist® Patient Education Liaisons

Alnylam Patient Education Liaisons

A Case Manager also can help connect you with a Patient Education Liaison (PEL). PELs have backgrounds in nursing, and are experienced in educating people and family members about PH1. Your PEL can help you in a variety of ways, including:

Supporting you with disease education

Providing you with product information

Connecting you to additional resources

Answering questions about treatment with OXLUMO

In addition, PELs help facilitate educational events about PH1 in communities around the United States. Talk to a Case Manager about finding an event in your area, or request a conversation with a PEL. Talk to a PEL ›

The purpose of Alnylam Patient Education Liaisons (PELs) is to provide education to patients, their families, and caregivers

PELs are employees of Alnylam Pharmaceuticals; They are not acting as healthcare providers and are not part of your healthcare team

PELs do not provide medical care or advice

All diagnosis and treatment decisions should be made by you and your doctor

What additional resources does Alnylam Assist™ offer?

Downloadable educational materials about PH1 and treatment with OXLUMO, as well as links to advocacy groups that connect patients to the PH1 community. Find additional resources ›

Alnylam Assist® - Questions Icon

Find answers to other

Frequently Asked Questions ›

Alnylam Assist® get started icon

See How to Get Started

Once you and your doctor decide to begin treatment with OXLUMO, we'll work with your healthcare team to start the process.

How to Get Started

Alnylam Assist® Case Manager Kevin

Call Kevin


Monday - Friday,
8am - 6pm

Alylam Separator Triangles


The most common side effect of OXLUMO is injection site reaction (redness, swelling, pain, bruising, itching, and discoloration at the site of injection). These are not all the possible side effects of OXLUMO. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

OXLUMO has not been studied in pregnant or breastfeeding women. Talk to your doctor about the risk of taking OXLUMO if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.


OXLUMO is a prescription medicine for the treatment of primary hyperoxaluria type 1 (PH1) to lower oxalate in urine and blood in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.